https://orcid.org/0000-0002-6442-1707
References
- Rossi E, Schinzari G, Maiorano BA, Indellicati G, Di Stefani A, Pagliara MM, Fragomeni SM, De Luca EV, Sammarco MG, Garganese G, et al. Efficacy of immune checkpoint inhibitors in different types of melanoma. Hum Vaccine Immunother. 2021;17:1,4–2. doi:https://doi.org/10.1080/21645515.2020.1771986.
- Bersanelli M, Petrelli F, Buti S, Stanganelli. Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials. Hum Vaccine Immunother. 2021:1–6. doi:https://doi.org/10.1080/21645515.2021.1902723.
- Luke JJ, Ascierto PA, Carlino MS, Gershenwald JE, Grob JJ, Hauschild A, Kirkwood JM, Long GV, Mohr P, Robert C, et al. KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020;16(3):4429–38. doi:https://doi.org/10.2217/fon-2019-0666.
- Wilson M, Geskin LJ, Carvajal RD, Mehnert JM, Chiuzan C, Leiby B, Senter K, Schuchter LM, Weight RM, Mastrangelo MJ, et al. Adjuvant nivolumab in high-risk stage IIb/IIc melanoma patients: results from investigator initiated clinical trial. J Clin Oncol. 2021;39(15_suppl):9583–958. doi:https://doi.org/10.1200/JCO.2021.39.15_suppl.9583.
- Ferraresi V, Vari S. Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma. Hum Vaccine Immunother. 2021:1–11. doi:https://doi.org/10.1080/21645515.2021.1971015.
- Sarver M, Brown MC, Rhodin KE, Salama April KS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccines Immunother. 2021:1–9. doi:https://doi.org/10.1080/21645515.2021.194398.
- Marconcini R, Pezzicoli G, Stucci LS, Sergi MC, Lospalluti L, Porta C, Tucci M. Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma. Hum Vaccines Immunother. 2021:1–9. doi:https://doi.org/10.1080/21645515.2021.1980315.
- Huppert LA, Daud AI. Intratumoral therapies and in-situ vaccination for melanoma. Hum Vaccines Immunother. doi:https://doi.org/10.1080/21645515.2021.1890512.
- Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Casà C, Di Stefani A, Pagliara MM, D’Aviero A, Schinzari G, Chiesa S, et al. Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccines Immunother. 2021:1–8. doi:https://doi.org/10.1080/21645515.2021.1903827.
- Bibbò S, Ianiro G, Giambò F, Settanni CR, Cammarota G, Gasbarrini A. Role of gut microbiome on immunotherapy efficacy in melanoma. Hum Vaccines Immunother. 2021:1–6. doi:https://doi.org/10.1080/21645515.2021.1926759.
- Sollena P, Cappilli S, Federico F, Schinzari G, Tortora G, Peris K. “Skin rashes” and immunotherapy in melanoma: distinct dermatologic adverse events and implications for therapeutic management. Hum Vaccines Immunother. 2021:1–8. doi:https://doi.org/10.1080/21645515.2021.1889449.
- Rossi E, Zizzari IG, Di Filippo A, Acampora A, Pagliara MM, Sammarco MG, Simmaco M, Lionetto L, Botticelli A, Bria E, et al. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study. Hum Vaccines Immunother. 2022:1–10. doi: https://doi.org/10.1080/21645515.2022.2034377 .